| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| Non-small Cell Lung Cancer |
| 5540- | BBM, | Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways |
| - | vitro+vivo, | NSCLC, | NA |
| 5180- | BBR, | Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth |
| - | in-vitro, | NSCLC, | NA |
| 4920- | PEITC, | Cisplatin, | PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p |
| - | vitro+vivo, | NSCLC, | A549 |
| 4662- | RES, | A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 5103- | SK, | Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor |
| - | in-vitro, | NSCLC, | A549 |
| - | in-vitro, | NSCLC, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:19 Cells:% prod#:% Target#:4 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid